BioSēq™ provides mechanistic insight into the human-relevant genes and pathways modulated by your bioactive — mapping worm DEGs to their human orthologs and enriched pathways.
In vivo transcriptomics in weeks — not years.
Same number as humans, with 60–80% orthologs.
One worm day maps to ~2.85 human years.
Every cell observable in real time under a microscope.
Cell death, RNAi, GFP imaging, microRNA (2024).
Swipe to compare →
| Capability | Cell assays | C. elegans (TrueBioactives™) | Rodent studies | Clinical study |
|---|---|---|---|---|
| Whole living organism | No | Yes | Yes | Yes |
| Absorption and metabolism included | No | Yes | Yes | Yes |
| Uses vertebrate animals | No | No | Yes | — |
| Pathways mapped to human orthologues | Partly | Yes | Yes | — |
| Speed | Fast | Eight weeks | Slow | Slowest |
| Cost | Low | Moderate | High | Highest |
— not applicable.
Your ingredient at a target dose, dosed to C. elegans on the Infinity Chip.
Bulk RNA-seq across three technical replicates.
Worm DEGs mapped to human orthologs with a homology score.
Enriched human pathways and candidate health benefits.
The organism-on-chip and in vivo transcriptomics platform behind BioSēq has been validated in orbit under federal funding and documented in the peer-reviewed literature.